Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Good morning, and welcome to the Axsome Therapeutics Third ...

Cash, cash equivalents, marketable securities and restricted cash as of October 2, 2024 totaled approximately $642 million Achieved positive topline trial results ...

Submitted New Drug Application (NDA) to FDA for TNX-102 SL for fibromyalgia based on two statistically significant Phase 3 studiesGranted Fast ...

Tonix Medicines, our commercial subsidiary, markets Zembrace® SymTouch® (sumatriptan injection) 3 mg and Tosymra® (sumatriptan nasal spray) 10 mg for the treatment of acute migraine with or without ...

3 treatment related adverse events. Regarding the pain trial ... The Company's proprietary product pipeline includes treatments for CNS disorders such as acute migraine and serious lung diseases such ...

Joe McKay tried everything medicine had to offer for the blinding headaches that began in the months after 9/11, when the ...

A Blackburn woman died from an insulin overdose after the death of her husband and her dad's cancer diagnosis, an inquest heard. Margaret Bamford, 49, was taken to Royal Blackburn Hospital on August ...

Cullgen is also evaluating CG009301, a GSPT1 degrader for the treatment of blood cancers including relapsed/refractory acute myeloid ... The Company's proprietary product pipeline includes treatments ...

Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases. Our diverse neuroscience ...

The next day, still wearing yesterday’s knickers, Dom and I were helicoptered to a clearing some distance from the camp.

A mum whose little girl started to have trouble with balance - then with doing up buttons on her school shirt, at first ...